Brent Ramirez

I was diagnosed with advanced prostate cancer almost 8 years ago. Shortly after my diagnosis, I met with Dr. Sartor for his recommendation on the best treatment. After reviewing my case, he stated “this is a nasty beast, but I have a plan”. Because of his extensive knowledge of and research in prostate cancer, he has had a plan for attacking my disease every step of the way, changing treatments as needed to outsmart my aggressive cancer. One of the first steps was to send me for a PSMA scan at Johns Hopkins, one of the few places offering this diagnostic tool back in 2017. This test is now a standard of care in treating prostate cancer.

One of the first steps was to send me for a PSMA scan at Johns Hopkins, one of the few places offering this diagnostic tool back in 2017. This test is now a standard of care in treating prostate cancer. Dr. Sartor was one of the main contributors using the PSMA technology to establish a targeted radiotherapy called Lutetium177, which was approved by the FDA in 2023. Dr. Sartor is now on a quest to use the same technology but with different molecules and Big Pharma is waking up to the potential to use this technology to treat other cancers. This is the kind of return on investment we see from funding Dr. Sartor’s research. I am a living example of the results possible. So many men benefit from the support this community provides to Dr. Sartor’s work.

I encourage and thank you for investing in the advancement of prostate cancer treatment.